ELI LILLY AND COMPANY (LLY) Dividend Safety
- Dividend payout ratio · 12 months: Value 21.66%; Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | 21.66% | Cash dividends paid / net income. Period ending 2026-06-30. $5.79B ÷ $26.71B × 100 ≈ 21.66% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | 5.79B USD | Payments of Dividends |
| Net income · 12 months | 26.71B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | $5.79B | $26.71B | 21.66% |
| 2026-03-31 | $5.59B | $25.28B | 22.10% |
| 2025-12-31 | $5.38B | $20.64B | 26.09% |
| 2025-09-30 | $5.21B | $18.41B | 28.28% |
| 2025-06-30 | $5.03B | $13.80B | 36.46% |
| 2025-03-31 | $4.86B | $11.11B | 43.74% |
| 2024-12-31 | $4.68B | $10.59B | 44.20% |
| 2024-09-30 | $4.53B | $8.37B | 54.12% |
| 2024-06-30 | $4.38B | $7.34B | 59.60% |
| 2024-03-31 | $4.22B | $6.14B | 68.77% |
| 2023-12-31 | $4.07B | $5.24B | 77.65% |
| 2023-09-30 | $3.94B | $4.99B | 78.90% |
| 2023-06-30 | $3.80B | $6.50B | 58.51% |
| 2023-03-31 | $3.67B | $5.69B | 64.49% |
| 2022-12-31 | $3.54B | $6.24B | 56.62% |
| 2022-09-30 | $3.42B | $6.03B | 56.76% |
| 2022-06-30 | $3.31B | $5.69B | 58.21% |
| 2022-03-31 | $3.20B | $6.13B | 52.17% |
| 2021-12-31 | $3.09B | $5.58B | 55.30% |
| 2021-09-30 | $2.98B | $5.97B | 49.95% |
| 2021-06-30 | $2.88B | $6.07B | 47.52% |
| 2021-03-31 | $2.79B | $6.09B | 45.80% |
| 2020-12-31 | $2.69B | $6.19B | 43.38% |
| 2020-09-30 | $2.60B | $5.57B | 46.73% |
| 2020-06-30 | $2.52B | $5.62B | 44.86% |
| 2020-03-31 | $2.44B | $5.53B | 44.17% |
| 2019-12-31 | $2.41B | $8.32B | 28.97% |
| 2019-09-30 | $2.40B | $7.95B | 30.14% |
| 2019-06-30 | $2.38B | $7.84B | 30.35% |
| 2019-03-31 | $2.36B | $6.26B | 37.75% |
| 2018-12-31 | $2.31B | $3.23B | 71.53% |
| 2018-09-30 | $2.29B | $450.10M | 508.22% |
| 2018-06-30 | $2.26B | $-143.80M | -1573.44% |
| 2018-03-31 | $2.23B | $1.12B | 198.56% |
| 2017-12-31 | $2.19B | $-204.10M | -1074.03% |
| 2017-09-30 | $2.18B | $2.22B | 98.22% |
| 2017-06-30 | $2.18B | $2.45B | 88.89% |
| 2017-03-31 | $2.17B | $2.19B | 99.13% |
| 2016-12-31 | $2.16B | $2.74B | 78.85% |
| 2016-09-30 | $2.15B | $2.44B | 87.99% |
| 2016-06-30 | $2.14B | $2.47B | 86.75% |
| 2016-03-31 | $2.14B | $2.32B | 92.18% |
| 2015-12-31 | $2.13B | $2.41B | 88.33% |
| 2015-09-30 | $2.12B | $2.36B | 89.85% |
| 2015-06-30 | $2.12B | $2.06B | 102.84% |
| 2015-03-31 | $2.10B | $2.19B | 96.03% |
| 2014-12-31 | $2.10B | $2.39B | 87.90% |
| 2014-09-30 | $2.10B | $2.69B | 78.26% |
| 2014-06-30 | $2.11B | $3.39B | 62.13% |
| 2014-03-31 | $2.11B | $3.86B | 54.69% |
| 2013-12-31 | $2.12B | $4.68B | 45.27% |
| 2013-09-30 | $2.14B | $4.78B | 44.73% |
| 2013-06-30 | $2.16B | $4.91B | 43.94% |
| 2013-03-31 | $2.17B | $4.63B | 47.00% |
| 2012-12-31 | $2.19B | $4.09B | 53.50% |
| 2012-09-30 | $2.18B | $4.12B | 52.99% |
| 2012-06-30 | $2.18B | $4.03B | 54.10% |
| 2012-03-31 | $2.18B | $4.30B | 50.70% |
| 2011-12-31 | $2.18B | $4.35B | 50.14% |
| 2011-09-30 | $2.18B | $4.66B | 46.80% |
| 2011-06-30 | $2.18B | $4.73B | 46.23% |
| 2011-03-31 | $2.17B | $4.88B | 44.48% |
| 2010-12-31 | $2.17B | $5.07B | 42.71% |
| 2010-09-30 | $2.16B | $4.82B | 44.88% |
| 2010-06-30 | $2.15B | $4.45B | 48.32% |
| 2010-03-31 | $2.15B | $4.26B | 50.53% |
| 2009-12-31 | $2.15B | $4.33B | 49.72% |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) |
| 2008-12-31 | $2.06B | $-2.07B | -99.27% |
| 2008-09-30 | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) |
| 2007-12-31 | $1.85B | $2.95B | 62.77% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |